Nazlı GÜLSOY KIRNAP, Özlem TURHAN İYİDİR, Yusuf BOZKUŞ, Şerife Mehlika IŞILDAK, Cüneyd ANIL, Sevde Nur FIRAT, Canan DEMİR, Aslı NAR, Neslihan BAŞÇIL TÜTÜNCÜ

The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

Background/aim: Overt thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism SCH are limited. Subclinical hyperthyroidism induction by administering L-Thyroxine LT4 is the standard treatment method in differentiated thyroid carcinoma DTC follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC patients followed-up with exogenous SCH. Materials and methods: The patients were divided into exogenous SCH by LT4-DTC n = 127 , euthyroid-DTC n = 66 and exogenous euthyroid-benign thyroid noduüle BTN who underwent thyroidectomy for benign thyroid pathology n = 85 groups. Results: The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group 27.5%, n = 35 vs. 9.4%, n = 8 P = 0.001 . TSH levels and Beck anxiety inventory BAI scores were significantly negatively correlated P = 0.009 r = -0.16 . Free T4 and BAI were significantly positively correlated P = 0.04 r = 0.4 . The groups were similar in terms of depression severity P = 0.15 . Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey. Conclusion: LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.

Keywords:

Beck anxiety and depression inventory, differentiated thyroid carcinoma, SF-36 quality of life survey, subclinical hyperthyroidism, TSH suppression,

___

1. Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Hormones (Athens, Greece) 2010; 9 (2): 103-108. doi: 10.14310/ horm.2002.1260
2. Pacini F, Castagna MG. New insight in the follow-up strategies of differentiated thyroid cancer. Journal of Endocrinological Investigation 2012; 35 (6 Suppl): 36-39.
3. Donangelo I, Braunstein GD. Update on subclinical hyperthyroidism. American Family Physician 2011;83 (8): 933-938.
4. Collet TH, Gussekloo J, Bauer DC, Den Elzen WP, Cappola AR et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine 2012;172 (10): 799-809. doi: 10.1001/archinternmed.2012.402
5. Vigario PS, Chachamovitz DS, Cordeiro MF, Teixeira PF, de Castro CL et al. Effects of physical activity on body composition and fatigue perception in patients on thyrotropin-suppressive therapy for differentiated thyroid carcinoma. Thyroid 2011; 21 (7): 695-700. doi: 10.1089/thy.2010.0052
6. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal consequences of thyrotoxicosis. The Journal of Endocrinology 2012; 213 (3): 209-221. doi: 10.1530/JOE-12-0059
7. De Oliveira Chachamovitz DS, Dos Santos Vigario P, Nogueira Cordeiro MF, de Castro CLN, Vaisman M et al. Quality of life, muscle strength, and fatigue perception in patients on suppressive therapy with levothyroxine for differentiated thyroid carcinoma. American Journal of Clinical Oncology 2013; 36 (4): 354-361.doi: 10.1097/COC.0b013e318248d864
8. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003; 25 (5): 349-356. doi: 10.1002/hed.10217
9. Blum MR, Wijsman LW, Virgini VS, Bauer DC, Den Elzen WP et al. Subclinical thyroid dysfunction and depressive symptoms among the elderly: a prospective cohort study. Neuroendocrinology 2016; 103 (3-4): 291-299. doi: 10.1159/000437387
10. Medici M, Direk N, Visser WE, Korevaar TI, Hofman A et al. Thyroid function within the normal range and the risk of depression: a population-based cohort study. The Journal of Clinical Endocrinology and Metabolism 2014; 99 (4): 1213- 1219. doi: 10.1210/jc.2013-3589
11. Sait Gönen M, Kisakol G, Savas Cilli A, Dikbas O, Gungor K et al. Assessment of anxiety in subclinical thyroid disorders. Endocrine Journal 2004; 51 (3): 311-315. doi: 10.1507/ endocrj.51.311
12. Feldkamp J. Subclinical hyperthyroidism. Deutsche Medizinische Wochenschrift 2013; 138 (42): 2146-2150. doi: 10.1055/s-0033-1343278
13. Placidi GP, Boldrini M, Patronelli A, Fiore E, Chiovato L et al. Prevalence of psychiatric disorders in thyroid diseased patients. Neuropsychobiology 1998; 38 (4): 222-225. doi: 10.1159/000026545
14. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008; 29 (1): 76-131. doi: 10.1210/er.2006-0043
15. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S et al. Quality of life in patients with thyroid cancer compared with the general population. Thyroid 2012; 22 (2): 117-124. doi: 10.1089/thy.2011.0139
16. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961; 4: 561-571. doi: 10.1001/ archpsyc.1961.01710120031004
17. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988; 56 (6): 893-897. doi: 10.1037//0022-006x.56.6.893
18. Hisli N. Beck depresyon envanterinin üniversite öğrencileri için geçerliliği, güvenilirliği (a reliability and validity study of Beck depression inventory in a university student sample). Journal of Psychology 1989; 7: 3-13.
19. Ulusoy M, Sahin NH, Erkmen H. The Beck anxiety inventory: psychometric properties. Journal of Cognitive Psychotherapy 1998; 12 (2): 163-172.
20. Ware JE. Scoring the SF-36. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA, USA: The Health Institute, New England Medical Center; 1993. pp.1-11.
21. Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş AK. Form36 (KF-36)’nın Türkçe versiyonunun güvenilirliği ve geçerliliği. İlaç ve Tedavi Dergisi 1999; 12 (2): 102-106.
22. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroidstimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20 (2): 173-179. doi: 10.1089/thy.2009.0187
23. Vigario PS, Chachamovitz DS, Teixeira Pde F, Rocque Mde L, Santos ML, Vaisman M. Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma. Arquivos Brasileiros de Endocrinologia and Metabologia 2014; 58 (3): 274-281. doi: 10.1590/0004-2730000002968
24. Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology: the scientific basis of clinical practice. Washington, DC, USA: American Psychiatric Publishing; 2008.
25. Denicoff KD, Joffe RT, Lakshmanan MC, Robbins J, Rubinow DR. Neuropsychiatric manifestations of altered thyroid state. The American Journal of Psychiatry 1990; 147 (1): 94-99. doi: 10.1176/ajp.147.1.94
26. Greer S, Ramsay I, Bagley C. Neurotic and thyrotoxic anxiety: clinical, psychological and physiological measurements. The British Journal of Psychiatry 1973; 122 (570): 549-554. doi: 10.1192/bjp.122.5.549
27. Simon NM, Blacker D, Korbly NB, Sharma SG, Worthington JJ et al. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. Journal of Affective Disorders 2002; 69 (1-3): 209-217. doi: 10.1016/ s0165-0327(01)00378-0
28. Demet MM, Özmen B, Deveci A, Boyvada S, Adıgüzel H et al.. Depression and anxiety in hyperthyroidism. Archives of Medical Research 2002; 33 (6): 552-556. doi: 10.1016/s0188- 4409(02)00410-1
29. Munjack DJ, Palmer R. Thyroid hormones in panic disorder, panic disorder with agoraphobia, and generalized anxiety disorder. The Journal of Clinical Psychiatry 1988; 49 (6): 229- 231.
30. Engum A, Bjoro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function--a clinical fact or an artefact? Acta Psychiatrica Scandinavica 2002; 106 (1): 27-34. doi: 10.1034/j.1600-0447.2002.01250.x
31. Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. The Journal of Clinical Psychiatry 1993; 54 (2): 47-54.
32. Sulser F. Serotonin-norepinephrine receptor interactions in the brain: implications for the pharmacology and pathophysiology of affective disorders. The Journal of Clinical Psychiatry 1987; 48 Suppl:12-18.
33. Baldini IM, Vita A, Mauri MC, Amodei V, Carrisi M et al. Psychopathological and cognitive features in subclinical hypothyroidism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997; 21 (6): 925-935. doi:10.1016/s0278- 5846(97)00089-4
34. De Jongh RT, Lips P, Van Schoor NM, Rijs KJ, Deeg DJ et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. European Journal of Endocrinology 2011; 165 (4): 545-554. doi: 10.1530/EJE-11-0430
35. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bax JJ et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clinical Endocrinology 2006; 64 (3): 284-291. doi: 10.1111/j.1365-2265.2006.02458.x